API-CAT: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
API-CAT: Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
-
ナレーター：
-
著者：
このコンテンツについて
In this episode, Pip and Rich go beyond the abstract of the API-CAT study, a randomised controlled trial of apixaban 5 mg BD vs 2.5 mg BD in patients with cancer-associated PE or DVT who have completed 6 months of anticoagulation. The study reported non-inferiority for low-dose apixaban in terms of VTE recurrence with a reduction in clinical relevant bleeding. This is an interesting, practice-changing study but there is plenty of nuance and a lot to discuss. Don't miss this one!
HaemSTAR is an independent UK-wide network of registrars in clinical haematology, interested in promoting and performing research in classical haematology. Our focus is on collaborative projects across haemostasis & thrombosis, transfusion, general haematology, and obstetric haematology.
Hosted on Acast. See acast.com/privacy for more information.